Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since ...
High-throughput technologies such as array-comparative genomic hybridization and next-generation sequencing provide unprecedented levels of information regarding individual tumors and can be ...
Roche unveiled its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing. SBX chemistry, combined with an innovative sensor ...
Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of each ...
Has drug giant Roche finally cracked DNA sequencing? The company has recently claimed it can quickly and accurately decode the genome, in a way that’ … ...
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, ...
At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.
It’s bonkers.” Roche is not a newcomer to the sequencing space: the company bought Jonathan Rothberg’s 454 in 2007 for $140 million. 454 had just announced the completion of Jim Watson’s ...
MiSeq and 454 GS Junior launched by Life Technologies, Illumina and Roche, respectively. Compared to the high-throughput NGS platforms, these benchtop sequencers offer a lower data throughput ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback